What question did this study set out to answer?

The goal is to evaluate a less invasive ventricular assist device for providing cardiac support in cardiogenic shock.

March 23, 2026JHLT Open0 citationsOpen Access

A Novel Less Invasive Single Port Pulsatile Ventricular Assist Device

LLLi LiCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa JCJinsong Chen490 BioTech (United States)ZZZhongjiang Zhuang490 BioTech (United States)

Key Points

The goal is to evaluate a less invasive ventricular assist device for providing cardiac support in cardiogenic shock.
Developed a paracorporeal single port pulsatile ventricular assist device.
Tested device functionality using mock loops and in sheep (n=5).
Inserted a valved single lumen cannula without cardiopulmonary bypass.
Device achieved a flow rate of 6.2 L/min in mock loops.
Achieved a flow rate of 3.75 L/min in sheep with stable hemodynamics.
Hemoglobin and other blood cell counts remained stable over 6 hours.

Abstract

A less invasive paracorporeal single port pulsatile ventricular assist device (sppVAD) was developed for cardiogenic shock.This compact sppVAD includes a valved single lumen cannula (VSLC), valveless single port diaphragm displacement pump (spDDP), and portable console.A 33/27 Fr VSLC was fabricated for mock loop testing, a 28/25 Fr VSLC was made for 6 hr sheep testing (n=5, 44-52 kg), and valveless spDDP with portable console was made.The sppVAD (33/27 Fr VSLC) achieved 6.2 L/min flow in mock loop.In sheep, the 28/25 Fr VSLC was inserted without cardiopulmonary bypass from apex to ascending aorta within 1 min after apex exposure.The sppVAD achieved 3.75 L/min flow in sheep with stable hemodynamics.Hemoglobin, free hemoglobin, and platelet/white blood cell counts were unchanged through 6 hrs.Thus, our less invasive sppVAD achieved total left ventricle support with acceptable short-term hemocompatibility, showing good promise as a temporary VAD for cardiogenic shock.

问 AI

Bookmark

View Full Paper